Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
103 hedge funds and large institutions have $185M invested in Antares Pharma, Inc. in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 17 closing their positions.
264% more call options, than puts
Call options by funds: $640K | Put options by funds: $176K
112% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 17
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
30% more capital invested
Capital invested by funds: $142M → $185M (+$43.2M)
21% more funds holding
Funds holding: 85 → 103 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.8M |
| 2 |
State Street
Boston,
Massachusetts
|
+$5.54M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$3.88M |
| 4 |
PA
Perceptive Advisors
New York
|
+$3.83M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$8.5M |
| 2 |
BC
Broadfin Capital
New York
|
-$8.05M |
| 3 |
Millennium Management
New York
|
-$5.07M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$2.41M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.96M |
ATRS Hedge Fund Activity: Q2 2017 in Review
103 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2017, worth a combined $185M — up 30% from $142M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ATRS positions and 17 closed out — a net gain of 19 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $17.8M. The largest seller was Armistice Capital, cutting an estimated $8.5M.
- 103 institutional investors held Antares Pharma, Inc. (ATRS) as of Q2 2017, up from 85 in Q1 2017.
- Funds reported $185M of Antares Pharma, Inc. stock for Q2 2017, up 30% quarter-over-quarter.
- 36 funds opened new Antares Pharma, Inc. positions in Q2 2017 and 17 closed out, a net change of +19 holders.
- The largest Antares Pharma, Inc. buyer in Q2 2017 was BlackRock, an estimated $17.8M added.
- The largest Antares Pharma, Inc. seller in Q2 2017 was Armistice Capital, an estimated $8.5M sold.
Based on aggregated 13F filings for Q2 2017.